可注射水凝胶治疗心肌梗死的现状和展望

Present status and prospects of injectable hydrogels for treatment of myocardial infarction

由于现有临床治疗方案无法有效抑制心肌梗死(MI)后的负性心室重构,MI幸存者最终均发展至心力衰竭阶段,冠心病目前已取代风湿性心脏病成为我国患者心力衰竭的首要病因。寻求有效措施抑制MI后心室重构刻不容缓。水凝胶心肌内注射作为治疗MI的新方案,近几年取得了突飞猛进的发展。本文将对水凝胶心肌内注射治疗MI的原理、现状、可能机制及前景做一综述。

Survivors from myocardial infarction （MI） eventually develop heart failure due to the post-infarct ventricular remodeling which could not be suppressed by existing treatments. Currently, coronary heart disease has become the major cause of heart failure instead of rheumatic heart disease in China. For this reason, seeking effective treatment to prevent post-infarct ventricular remodeling is urgent. Intramyocardial injection of hydrogels as a new strategy for MI treatment has made great progress recently. This review discusses the principle, present status, mechanisms and prospects of injectable hydrogel therapies for MI.